Mitoglitazone Drug Asset Due Diligence Report 2026

This Mitoglitazone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Mitoglitazone can convert its Small molecule drug profile and MPC biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Mitoglitazone (query alias: Mitoglitazone)
Modality / target	Small molecule drug; MPC; SLC54 Mitochondrial pyruvate carriers inhibitors, Insulin sensitizers
Highest global status	Phase 2
Originator	Metabolic Solutions Development Co. LLC
Active developers	GT Metabolic Solutions, Inc.

The MCP disease footprint includes Alzheimer Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT01103414	Phase 2	Completed	356	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.
NCT00760578	Phase 2	Completed	86	Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test
NCT01374438	Phase 2	Completed	29	Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease

Phase 2; n=29; evaluation: not stated. Reported fields: Posterior cingulate(Mean) = 0.01 Ratio (Standard Deviation, 0.03); -; Posterior cingulate(Mean) = -0.02 Ratio (Standard Deviation, 0.03)

A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone™ in Type 2 Diabetic Patients

Phase 2; n=86; evaluation: not stated. Reported fields: Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test(Least Squares Mean) = 0.51 mmol/L (Standard Error, 0.340); -; -

Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Phase 2; n=356; evaluation: not stated. Reported fields: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.(Least Squares Mean): Mean Difference (Net) = -9.1(95% CI, -22.4 to 4.3), P-Value = 0.1819; Mean Difference (Net) = -18.4(95% CI, -31.4 to -5.4), P-Value = 0.0057; Mean Difference (Net) = -28.9(95% CI, -42.3 to -15.6), P-Value = <0.0001; Mean Difference (Net) = -31.0(95% CI, -43.8 to -18.2), P-Value = <0.0001; Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.(Least Squares Mean) = -27.2 mg/dL (Standard Error, 4.61); Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12.(Least Squares Mean): Mean Difference (Net) = -9.1(95% CI, -22.4 to 4.3), P-Value = 0.1819; Mean Difference (Net) = -18.4(95% CI, -31.4 to -5.4), P-Value = 0.0057; Mean Difference (Net) = -28.9(95% CI, -42.3 to -15.6), P-Value = <0.0001; Mean Difference (Net) = -31.0(95% CI, -43.8 to -18.2), P-Value = <0.0001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Mitoglitazone addresses Alzheimer Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: MPC records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2018-08-30	Poxel purchases DeuteRx's DRX-065 for NASH and other deuterated drugs targeting global metabolic, specialty, and rare diseases.	Phase 1	US$9.4M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Polymorphs of 5-(4-(2-(5-ethylpyridin-2-YL)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone)”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO